{"transactions":[{"id":932178,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:15:41.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":5.79,"underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0000905148-26-000311","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000311/form4.xml","form_type":"4"}},{"id":932177,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:15:41.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":11.4,"underlying":"Common Stock","underlying_shares":28200},"source":{"system":"sec-edgar","filing":"0000905148-26-000311","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000311/form4.xml","form_type":"4"}},{"id":1098967,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T06:14:09.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":23105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":23105,"derivative":{"exercise_price":7.8,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":23105},"source":{"system":"sec-edgar","filing":"0001655759-25-000126","document":"wk-form4_1751278445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000165575925000126/wk-form4_1751278445.xml","form_type":"4"}},{"id":1098966,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T06:14:09.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders,  subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":30166,"source":{"system":"sec-edgar","filing":"0001655759-25-000126","document":"wk-form4_1751278445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000165575925000126/wk-form4_1751278445.xml","form_type":"4"}},{"id":1113255,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T19:16:46.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":26550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":26550,"derivative":{"exercise_price":5.79,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0001104659-25-059044","document":"tm2517800-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465925059044/tm2517800-8_4seq1.xml","form_type":"4"}},{"id":1496306,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T17:52:14.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":9070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on May 29, 2024. The shares underlying the award shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":9070,"derivative":{"exercise_price":33.9,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":9070},"source":{"system":"sec-edgar","filing":"0001655759-24-000084","document":"wk-form4_1717192326.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000165575924000084/wk-form4_1717192326.xml","form_type":"4"}},{"id":1496305,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T17:52:14.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":5899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on May 29, 2024 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":14141,"source":{"system":"sec-edgar","filing":"0001655759-24-000084","document":"wk-form4_1717192326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000165575924000084/wk-form4_1717192326.xml","form_type":"4"}},{"id":1544496,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-09T08:11:28.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":28200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on April 8, 2024 and is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversary of the grant date until the third anniversary of the grant date, subject to the director's continued service."}],"balance_after":28200,"derivative":{"exercise_price":11.4,"expiration_date":"2034-04-07","underlying":"Common Stock","underlying_shares":28200},"source":{"system":"sec-edgar","filing":"0001104659-24-045003","document":"tm2411263-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924045003/tm2411263-2_4seq1.xml","form_type":"4"}},{"id":1848792,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:25:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":24948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 15, 2023. The shares underlying the award shall vest over three years in equal monthly installments through June 15, 2026."}],"balance_after":24948,"derivative":{"exercise_price":30.33,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":24948},"source":{"system":"sec-edgar","filing":"0001655759-23-000059","document":"wk-form4_1687296305.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000165575923000059/wk-form4_1687296305.xml","form_type":"4"}},{"id":1848791,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T17:25:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest over three years in equal annual installments through June 15, 2026."}],"balance_after":8242,"source":{"system":"sec-edgar","filing":"0001655759-23-000059","document":"wk-form4_1687296305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000165575923000059/wk-form4_1687296305.xml","form_type":"4"}},{"id":2244628,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:05:34.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."}],"balance_after":20000,"derivative":{"exercise_price":0.2,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-020933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924322020933/doc4.xml","form_type":"4"}},{"id":2343545,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Development & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-03-08T09:07:48.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":5.7,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001562180-22-002429","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000156218022002429/primarydocument.xml","form_type":"4"}},{"id":2564974,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Development & CMO"}}],"security":"Common Stock","published_at":"2021-09-17T16:27:21.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":1627,"price":26,"value":42302.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 5, 2021."}],"balance_after":1550000,"source":{"system":"sec-edgar","filing":"0001562180-21-005999","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000156218021005999/primarydocument.xml","form_type":"4"}},{"id":2564973,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Development & CMO"}}],"security":"Common Stock","published_at":"2021-09-17T16:27:21.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":58373,"price":26.0695,"value":1521754.9235,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 5, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.225, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":1551627,"source":{"system":"sec-edgar","filing":"0001562180-21-005999","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000156218021005999/primarydocument.xml","form_type":"4"}},{"id":2670136,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T16:05:22.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 11, 2021, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."}],"balance_after":20000,"derivative":{"exercise_price":2.28,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-023535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924321023535/doc4.xml","form_type":"4"}},{"id":2848804,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T18:50:36.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":76682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the underlying shares on February 15, 2022 and in 36 equal monthly installments thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."}],"balance_after":76682,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":76682},"source":{"system":"sec-edgar","filing":"0000899243-21-007181","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000089924321007181/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-05"}},{"id":2876278,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T17:20:41.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on February 15, 2022 and in 36 equal monthly installments thereafter."}],"balance_after":48000,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0000899243-21-005080","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616640/000089924321005080/doc4.xml","form_type":"4"}},{"id":2972706,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":100.27,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":2972705,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":6600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":47.77,"underlying":"Common Stock","underlying_shares":6600},"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":2972704,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":48.85,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":2972703,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":14,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":2972702,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":2972701,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":7.4,"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":2972700,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T20:20:50.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":4100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320031758/doc4.xml","form_type":"4"}},{"id":3101575,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T18:23:54.000Z","date":"2020-06-13","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-20-017505","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320017505/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-16"}},{"id":3101574,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T18:23:54.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0000899243-20-017505","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320017505/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-16"}},{"id":3102806,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-22T18:55:54.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":1800,"derivative":{"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0000899243-20-017415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320017415/doc4.xml","form_type":"4"}},{"id":3102805,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T18:55:54.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments after June 18, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3000,"derivative":{"exercise_price":100.27,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-017415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320017415/doc4.xml","form_type":"4"}},{"id":3108407,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-16T18:09:43.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-20-016689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320016689/doc4.xml","form_type":"4"}},{"id":3108406,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T18:09:43.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0000899243-20-016689","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924320016689/doc4.xml","form_type":"4"}},{"id":3113370,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T16:00:33.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 9, 2020, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."}],"balance_after":20000,"derivative":{"exercise_price":5.25,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-016146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924320016146/doc4.xml","form_type":"4"}},{"id":3487300,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-17T18:55:32.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":2300,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-19-017224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924319017224/doc4.xml","form_type":"4"}},{"id":3487299,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T18:55:32.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":6600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 13, 2019, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":6600,"derivative":{"exercise_price":47.17,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":6600},"source":{"system":"sec-edgar","filing":"0000899243-19-017224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924319017224/doc4.xml","form_type":"4"}},{"id":3504705,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-03T16:05:40.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from May 30, 2019, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."}],"balance_after":11000,"derivative":{"exercise_price":5.42,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-19-015382","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924319015382/doc4.xml","form_type":"4"}},{"id":3893453,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-14T16:07:24.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 12, 2018, such that this option is fully exercisable on June 12, 2019. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":11000,"derivative":{"exercise_price":48.85,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-18-016597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924318016597/doc4.xml","form_type":"4"}},{"id":3908390,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-04T16:15:06.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from May 31, 2018, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."}],"balance_after":11000,"derivative":{"exercise_price":5.15,"expiration_date":"2028-05-30","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-18-014889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924318014889/doc4.xml","form_type":"4"}},{"id":4007499,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:11:43.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":313797,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":24.01,"expiration_date":"2027-04-12","underlying":"Common Stock","underlying_shares":313797},"source":{"system":"sec-edgar","filing":"0001209191-18-017796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017796/doc4.xml","form_type":"4"}},{"id":4007498,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2018-03-07T18:11:43.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":35893,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents performance-based restricted stock awards (\"PSAs\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017796/doc4.xml","form_type":"4"}},{"id":4007497,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2018-03-07T18:11:43.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":29135,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":35893,"source":{"system":"sec-edgar","filing":"0001209191-18-017796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017796/doc4.xml","form_type":"4"}},{"id":4007496,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2018-03-07T18:11:43.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":84549,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":65028,"source":{"system":"sec-edgar","filing":"0001209191-18-017796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017796/doc4.xml","form_type":"4"}},{"id":4078467,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2018-02-02T19:25:14.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":29135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018."}],"balance_after":149577,"source":{"system":"sec-edgar","filing":"0001209191-18-007205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118007205/doc4.xml","form_type":"4"}},{"id":4182320,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2017-10-20T20:24:12.000Z","date":"2017-10-20","kind":"grant","acquired":true,"shares":35893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards (\"RSAs\") granted pursuant to the 2014 Equity Incentive Plan. The RSAs will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date:\n\nUp to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the \"FDA\") of JCAR017 in any indication within certain designated timeframes (the \"JCAR017 Milestone\"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement.\n\nUp to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes."}],"balance_after":120442,"source":{"system":"sec-edgar","filing":"0001209191-17-057691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117057691/doc4.xml","form_type":"4"}},{"id":4191701,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2017-10-04T19:31:49.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":7285,"price":44.7616,"value":326088.256,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were executed pursuant to a trading plan adopted by the reporting person on April 27, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $44.50 to $45.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":84549,"source":{"system":"sec-edgar","filing":"0001209191-17-056034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117056034/doc4.xml","form_type":"4"}},{"id":4278636,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-16T16:14:07.000Z","date":"2017-06-14","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 14, 2017, such that this option is fully exercisable on June 14, 2018. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan)."}],"balance_after":11000,"derivative":{"exercise_price":14,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-17-016565","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1552451/000089924317016565/doc4.xml","form_type":"4"}},{"id":4283765,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T16:35:25.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 09, 2017, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."}],"balance_after":11000,"derivative":{"exercise_price":14.2,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-17-016230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924317016230/doc4.xml","form_type":"4"}},{"id":4351360,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-17T19:58:57.000Z","date":"2017-04-13","kind":"grant","acquired":true,"shares":313797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest and become exercisable on April 13, 2018 and 1/48th of the shares subject to the option shall vest and become exercisable monthly thereafter."}],"balance_after":313797,"derivative":{"exercise_price":24.01,"expiration_date":"2027-04-12","underlying":"Common Stock","underlying_shares":313797},"source":{"system":"sec-edgar","filing":"0001209191-17-027173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117027173/doc4.xml","form_type":"4"}},{"id":4351359,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2017-04-17T19:58:57.000Z","date":"2017-04-13","kind":"tax_withholding","acquired":false,"shares":4793,"price":24.01,"value":115079.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of RSUs."}],"balance_after":91834,"source":{"system":"sec-edgar","filing":"0001209191-17-027173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117027173/doc4.xml","form_type":"4"}},{"id":4351358,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":68891,"kind":"person","name":"AGARWAL SUNIL","position":1,"cik":"0001616640","reported_name":"AGARWAL SUNIL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R & D"}}],"security":"Common Stock","published_at":"2017-04-17T19:58:57.000Z","date":"2017-04-13","kind":"grant","acquired":true,"shares":96627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 12.5% of the RSUs vested on April 13, 2017, 31.25% of the RSUs vest on April 13, 2018, and 18.75% of the RSUs vest on each of the second, third, and fourth anniversaries of April 13, 2017."}],"balance_after":96627,"source":{"system":"sec-edgar","filing":"0001209191-17-027173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117027173/doc4.xml","form_type":"4"}}]}